Special Issue "Hormone Therapies for Women"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Sex, Gender and Hormone Based Medicine".

Deadline for manuscript submissions: 15 January 2024 | Viewed by 1679

Special Issue Editors

Obstetrics and Gynecology, Villa Sofia Cervello Hospital, I.V.F. Public Center, University of Palermo, Palermo, Italy
Interests: reproductive medicine; IVF, STEM CELLS, ART; gender medicine; dometriosis; reproductive endocrinology; reproduction biology; sterility; hysteroscopy; reproduction; fertility gynaecological ultrasound; PCOS
Special Issues, Collections and Topics in MDPI journals
Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35128 Padua, Italy
Interests: infertility; PCOS; fertility preservation; gender medicine

Special Issue Information

Dear Colleagues,

Infertility is a detrimental condition that strongly affects couples, and it is expected to become more frequent worldwide. Different conditions, for both male and female partners, are responsible for infertility, accounting for structural diseases or more subtle and complex events. With this in mind, hormonal assessments play a key role in an infertility diagnosis, since their imbalance could be responsible for different outcomes. Moreover, gonadotropin administration is one of the leading medical treatments in assisted reproductive techniques (ARTs). In particular, the IVF/ICSI and IUI treatments require hormonal-controlled ovarian stimulation. In addition, new insights and proposals are provided regarding adjuvant therapies. In this scenario, we propose this Special Issue, which has the aim of moving the endocrinology field, addressing female and male infertility, forward. In particular, we aim to address two specific issues: PCOS and hypogonadotropic hypopituarism. We consider them of paramount importance, although they are often considered to be of secondary importance when dealing with IVF/ICSI procedures. Targeting this peculiar area of interest could increase both ART outcomes and the achievement of spontaneous pregnancy.

We are also grateful to receive papers with a gender approach, as well as those on the potential impacts of COVID-19 on fertility.

We would be grateful to receive original clinical and basic research articles, meta-analyses, and systematic reviews regarding the following topics:

1) PCOS and its impact on female infertility.

2) Hypogonadotropic hypopituarism diagnosis and therapy.

3) Hormone therapy and infertility.

4) Contraception.

5) Stem cells.

6) Gender medicine.

7) Medico-legal implications.

8) COVID-19 and hormones.

With the hope to have your contribution to help this field move forward,

Our best regards,

Dr. Giuseppe Gullo
Prof. Dr. Gaspare Cucinella
Dr. Giovanni Buzzaccarini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • reproductive medicine
  • hormone therapy
  • PCOS
  • gender medicine
  • contraception
  • medico-legal implications
  • inositol therapy
  • fertility preservation
  • psychological factors

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


20 pages, 589 KiB  
Systematic Review
Menstrual Cycle, Glucose Control and Insulin Sensitivity in Type 1 Diabetes: A Systematic Review
J. Pers. Med. 2023, 13(2), 374; https://doi.org/10.3390/jpm13020374 - 20 Feb 2023
Cited by 1 | Viewed by 1332
The correlation between the menstrual cycle and glucose control in type 1 diabetes has been the focus of several studies since the 1920s, but a few critical aspects made it particularly challenging to reach conclusive evidence. The aim of this systematic review is [...] Read more.
The correlation between the menstrual cycle and glucose control in type 1 diabetes has been the focus of several studies since the 1920s, but a few critical aspects made it particularly challenging to reach conclusive evidence. The aim of this systematic review is to reveal more solid information about the impact of the menstrual cycle on glycaemic outcomes and insulin sensitivity in type 1 diabetes and highlight the less researched areas. The literature was searched by two authors independently using PubMed/MEDLINE, Embase and Scopus (last search on 2 November 2022). The retrieved data did not allow us to perform a meta-analysis. We included 14 studies published between 1990 and 2022, with sample sizes from 4 to 124 patients. We found a wide heterogeneity in the definition of the menstrual cycle phases, glucose metrics, techniques for determining insulin sensitivity, hormonal assessment and other interfering factors considered, with an overall high risk of bias. There is no conclusive evidence, and published data do not allow us to achieve quantitative results. In a subset of patients, a possible worsening of insulin sensitivity and hyperglycaemia in the luteal phase could be observed. From the clinical standpoint, a cautious strategy based on patient-specific patterns can be considered until new, solid evidence is obtained. Full article
(This article belongs to the Special Issue Hormone Therapies for Women)
Show Figures

Figure 1

Back to TopTop